Harvard Business Review September 4, 2024
David Blumenthal, Bakul Patel

Summary: A challenge confronting the Food and Drug Administration — and other regulators around the world — is how to regulate generative AI. The approach it uses for new drugs and devices isn’t appropriate. Instead, the FDA should be conceiving of LLMs as novel forms of intelligence. It should employ similar approaches to those it applies to clinicians.

Generative AI has arrived in medicine. Normally, when a new device or drug enters the U.S. market, the Food and Drug Administration (FDA) reviews it for safety...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Govt Agencies, Regulations, Technology
Sam Altman says the kid he’s expecting soon will never be smarter than AI, but thinks this ability will be valuable
Private Sector Advances Nuclear Fusion With AI – New Plant To Open Soon
Time To Take The Low Expectations Out Of GenAI
Key Ways That Generative AI Can Spur You To Be Frugal On An Enduring Lifelong Basis
Data Storage And Memory Powers AI At The 2025 CES

Share This Article